Antigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.Carbohydrate Sequence: The sequence of carbohydrates within POLYSACCHARIDES; GLYCOPROTEINS; and GLYCOLIPIDS.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Carbohydrates: The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n.Second-Look Surgery: A followup operation to examine the outcome of the previous surgery and other treatments, such as chemotherapy or radiation therapy.Breast Neoplasms: Tumors or cancer of the human BREAST.CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Carbohydrate Metabolism: Cellular processes in biosynthesis (anabolism) and degradation (catabolism) of CARBOHYDRATES.Dietary Carbohydrates: Carbohydrates present in food comprising digestible sugars and starches and indigestible cellulose and other dietary fibers. The former are the major source of energy. The sugars are in beet and cane sugar, fruits, honey, sweet corn, corn syrup, milk and milk products, etc.; the starches are in cereal grains, legumes (FABACEAE), tubers, etc. (From Claudio & Lagua, Nutrition and Diet Therapy Dictionary, 3d ed, p32, p277)Drug Discovery: The process of finding chemicals for potential therapeutic use.Glycomics: The systematic study of the structure and function of the complete set of glycans (the glycome) produced in a single organism and identification of all the genes that encode glycoproteins.Zinc Acetate: A salt produced by the reaction of zinc oxide with acetic acid and used as an astringent, styptic, and emetic.BooksDrug Design: The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.Glycoconjugates: Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)PolysaccharidesPharmacies: Facilities for the preparation and dispensing of drugs.History, 20th Century: Time period from 1901 through 2000 of the common era.Faculty: The teaching staff and members of the administrative staff having academic rank in an educational institution.Pharmacy: The practice of compounding and dispensing medicinal preparations.Education, Pharmacy: Formal instruction, learning, or training in the preparation, dispensing, and proper utilization of drugs in the field of medicine.GermanyFaculty, Medical: The teaching staff and members of the administrative staff having academic rank in a medical school.Germany, WestSchools, Pharmacy: Educational institutions for individuals specializing in the field of pharmacy.Faculty, Dental: The teaching staff and members of the administrative staff having academic rank in a dental school.N-Acetylglucosaminyltransferases: Enzymes that catalyze the transfer of N-acetylglucosamine from a nucleoside diphosphate N-acetylglucosamine to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-.Oligosaccharides: Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Exocrine Glands: Glands of external secretion that release its secretions to the body's cavities, organs, or surface, through a duct.Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Serous Membrane: A thin lining of closed cavities of the body, consisting of a single layer of squamous epithelial cells (MESOTHELIUM) resting on a thin layer of CONNECTIVE TISSUE, and covered with secreted clear fluid from blood and lymph vessels. Major serous membranes in the body include PERICARDIUM; PERITONEUM; and PLEURA.Lung Neoplasms: Tumors or cancer of the LUNG.FucoseLectins: Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition.Hepatitis, Infectious Canine: A contagious disease caused by canine adenovirus (ADENOVIRUSES, CANINE) infecting the LIVER, the EYE, the KIDNEY, and other organs in dogs, other canids, and bears. Symptoms include FEVER; EDEMA; VOMITING; and DIARRHEA.Molecular Mimicry: The structure of one molecule that imitates or simulates the structure of a different molecule.Endothelial Cells: Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Lawyers: Persons whose profession is to give legal advice and assistance to clients and represent them in legal matters. (American Heritage Dictionary, 3d ed)Pleura: The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid.Pleural Neoplasms: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.Microscopy: The use of instrumentation and techniques for visualizing material and details that cannot be seen by the unaided eye. It is usually done by enlarging images, transmitted by light or electron beams, with optical or magnetic lenses that magnify the entire image field. With scanning microscopy, images are generated by collecting output from the specimen in a point-by-point fashion, on a magnified scale, as it is scanned by a narrow beam of light or electrons, a laser, a conductive probe, or a topographical probe.Partnership Practice: A voluntary contract between two or more doctors who may or may not share responsibility for the care of patients, with proportional sharing of profits and losses.Dental Casting Technique: The process of producing a form or impression made of metal or plaster using a mold.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Malpractice: Failure of a professional person, a physician or lawyer, to render proper services through reprehensible ignorance or negligence or through criminal intent, especially when injury or loss follows. (Random House Unabridged Dictionary, 2d ed)Epitopes, T-Lymphocyte: Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.Vaccines, Contraceptive: Vaccines or candidate vaccines used to prevent conception.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Epitopes: Sites on an antigen that interact with specific antibodies.NK Cell Lectin-Like Receptor Subfamily K: An activating NK cell lectin-like receptor subfamily that regulates immune responses to INFECTION and NEOPLASMS. Members of this subfamily generally occur as homodimers.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Thailand: Formerly known as Siam, this is a Southeast Asian nation at the center of the Indochina peninsula. Bangkok is the capital city.Hysterectomy: Excision of the uterus.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Endometrium: The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.Saudi ArabiaEndometrial Hyperplasia: Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.Hysterectomy, Vaginal: Removal of the uterus through the vagina.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.

The distribution of ganglioside-like moieties in peripheral nerves. (1/692)

GM1 ganglioside has been implicated as a target of immune attack in some diseases of the peripheral nervous system. Anti-GM1 ganglioside antibodies are associated with certain acquired immune-mediated neuropathies. It is not clear how anti-GM1 antibodies cause nerve dysfunction and injury; however, sodium and/or potassium ion channel dysfunction at the node of Ranvier has been implicated. To gain insight into the pathogenesis of these neuropathies, we examined the distribution of GM1 ganglioside and Gal(beta1-3)GalNAc moieties in nerve fibres and their relationship to voltage-gated sodium and potassium (Kv1.1, 1.5) channels at the nodes of Ranvier in peripheral nerves from human, rat and dystrophic mice. Gal(beta1-3)GalNAc moieties were localized via the binding of cholera toxin and peanut agglutinin. As a control for the specificity of these findings, we compared the distribution of GM1 moieties to that of the ganglioside GT1b. Our study provides definitive evidence for the presence of Gal(beta1-3)GalNAc bearing moieties on the axolemmal surface of mature myelinated fibres and on Schwann cells. Gal(beta1-3)GalNAc binding sites did not have an obligatory co-localization with voltage-gated sodium channels or the potassium ion channels Kv1.1 and Kv1.5 and are thus not likely carried by these ion channels. In contrast with Gal(beta1-3)GalNAc, GT1b-like moieties are restricted to the axolemma.  (+info)

A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. (2/692)

Aberrant glycosylation of mucins leads to the exposure of cryptic carbohydrate antigens at the surface of carcinoma cells, which, therefore, represent potent targets for anticancer therapeutic vaccines. To date, the development of immunogens to stimulate immune response to such saccharidic antigens is based on carbohydrate conjugation to carrier proteins. However, these traditional protein conjugates are poorly defined in chemical composition and structure. As an alternative, we synthesized a multiple antigenic O-linked glycopeptide (MAG) carrying the carbohydrate Tn antigen associated with a CD4+ T-cell epitope (MAG:Tn-PV). This fully synthetic immunogen is highly defined in composition and carries a high saccharidic epitope ratio over the entire molecule. The MAG:Tn-PV was able to induce anti-Tn IgG antibodies that recognize human tumor cell lines. A therapeutic immunization protocol performed with this fully synthetic immunogen increased the survival of tumor-bearing mice. Thus, the accurately defined and versatile MAG system represents an efficient strategy to induce carbohydrate-specific antitumor immune responses but may also be applicable to the prevention of infectious diseases, if it is based on bacterial oligosaccharides.  (+info)

T and Tk antigen activation in necrotising enterocolitis: manifestations, severity of illness, and effectiveness of testing. (3/692)

AIMS: To determine if T or Tk antigen activation is associated with different and more severe manifestations of illness in infants with necrotising enterocolitis (NEC); and if a policy of testing infants with suspected sepsis or NEC for T and Tk antigen activation is effective. METHODS: A case-control study of infants with confirmed NEC, born after the introduction of screening, was undertaken:17 activated infants were compared with 28 non-activated controls, matched for gestation and weight. A historical control study compared the outcome of infants before and after the introduction of testing. RESULTS: Of 201 infants with confirmed NEC, 27 were T or Tk antigen activated-10 (9%) before and 17 (19%) after the introduction of testing. T or Tk antigen activated infants had a significantly higher mortality (35% vs 7%); more frequent (71% vs 21%) and severe haemolysis, hyperkalaemia, renal impairment, acidosis; and they received more colloid for resuscitation. While only known activated infants in both time periods were managed with the use of low titre T antibody blood products, there was a significant increase in mortality (odds ratios 2.6; 95% CI 1.2, 5.6) and incidence of surgery (OR 2.7; 1.5, 4.9) after the introduction of testing. The increased mortality (OR 2.6; 0.8, 5.2) and incidence of surgery (OR 1.8; 0.9, 3.7) were no longer significant after adjustment for several perinatal risk factors. CONCLUSIONS: In a retrospective case-control study, routine testing of at risk infants increased the detection rate of T and Tk antigen activation. The use of low titre T plasma products in these patients did not reduce mortality compared with historical controls. A randomised controlled trial of testing in at risk infants, or of the use of low titre T plasma products in babies with NEC and T activation, is warranted.  (+info)

Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. (4/692)

BACKGROUND: A new, fully automated method that measures the breast cancer-associated glycoprotein CA27.29 has become commercially available. The aim of the present study was to compare this CA27.29 assay with the assay that measures CA15.3 in primary breast cancer. METHODS: The study was performed retrospectively on preoperative serum samples collected from 275 patients with untreated primary breast cancer (154 node positive and 121 node negative). Eighty-three healthy control subjects were also evaluated. CA27.29 was measured using the fully automated Chiron Diagnostics immunochemiluminescent system (ACS:180 BR). CA15.3 was measured with a manual immunoradiometric method (Centocor CA15.3 RIA). RESULTS: In healthy subjects, CA15.3 was significantly higher than CA27.29 (P <0. 0001). On the other hand, in breast cancer patients CA27.29 was higher than CA15.3 (P = 0.013). The mean value found in the control group plus 2 SD was chosen as the positive/negative cutoff point. The overall positivity rates were 34.9% for CA27.29 and 22.5% for CA15.3. The area under the ROC curve was greater (P <0.001) for CA27. 29 (0.72) than for CA15.3 (0.61). Both markers showed a statistically significant, direct relationship, with pathological stage being higher in node-positive than in node-negative cases and in larger than in smaller tumors. Neither CA27.29 nor CA15.3 showed significant associations with age, menopausal status, or tumor receptor status. CONCLUSIONS: CA27.29 discriminates primary breast cancer from healthy subjects better than CA15.3, especially in patients with limited disease. Prospective studies are necessary to confirm this conclusion.  (+info)

Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. (5/692)

A large naive human single-chain (sc) Fv phage library was used to search for tumor-associated antigens by panning with a lung adenocarcinoma cell line, 1264, and counter-selecting with a nontumor bronchial epithelial cell line, BEAS-2B. After three rounds of subtractive panning, 239 of 673 clones analyzed bound selectively to 1264 tumor cells in a phage ELISA. Diversity analysis of these tumor-selective clones by BstNI fingerprinting and nucleotide sequencing revealed 14 distinct scFv fragments. Four clones bound selectively to 1264 over BEAS-2B cells when analyzed by a more discriminating flow cytometric assay using scFv. Moreover, these clones showed only limited cross-reactivity to several primary human cell lines. One clone, LU30, also cross-reacted strongly with the lung adenocarcinoma line, A549. The LU30 antigen was identified as decay-accelerating factor (CD55) by expression cloning from a 1264 cDNA library. The mean number of decay-accelerating factor molecules on the surface of 1264 and BEAS cells used for panning and counter-selection was estimated as 75,000 +/- 5,000 and 13,000 +/- 10,000, respectively. Thus, phage library panning combined with expression cloning permits identification of antibodies and their cognate antigens for proteins that are differentially expressed on the surface of distinct cell populations.  (+info)

The cysteine-rich region of the Entamoeba histolytica adherence lectin (170-kilodalton subunit) is sufficient for high-affinity Gal/GalNAc-specific binding in vitro. (6/692)

Adherence of Entamoeba histolytica trophozoites to colonic mucin, epithelium, and other target cells is mediated by the amebic Gal/GalNAc lectin. We constructed in vitro expression vectors containing full-length (residues 1 to 1280), cysteine-poor (1 to 353 and 1 to 480), and cysteine-rich (356 to 1143 and 480 to 900) fragments of the gene encoding the heavy subunit of the adherence lectin, hgl2. In vitro transcription followed by translation using a nuclease-treated rabbit reticulocyte lysate system was carried out. Immunoreactivity of in vitro-translated Hgl2 was confirmed by immunoprecipitation with lectin-specific monoclonal antibodies (MAbs) 1G7 and 8A3, which recognize linear epitopes. Protein disulfide isomerase (PDI) refolding of Hgl2 enhanced immunoreactivity (P < 0.05) with the conformationally dependent MAb 3F4. Binding of PDI-refolded full-length (P < 0.001) and cysteine-rich (P = 0.005) Hgl2 to CHO cells was galactose dependent and competitively inhibited by native hololectin (50% inhibitory concentration of 39.6 ng/ml). The cysteine-poor region (1 to 353) did not bind CHO cells. Both full-length (1 to 1280) and cysteine-rich (356 to 1143) Hgl2 bound the glyconeoconjugate GalNAc(19)BSA in a GalNAc-specific manner. The smaller cysteine-rich fragment (480 to 900) also exhibited GalNAc-specific binding but to a lesser extent (P < 0.05) than residues 1 to 1280 and 356 to 1143. Neither the cysteine-poor fragment (1 to 480), luciferase (protein control), nor control translation reactions (without hgl2 lectin mRNA) bound GalNAc(19)BSA. Binding to GalNAc(19)BSA was shown to be dependent on the concentration of GalNAc(19)BSA coated in each well or (35)S-lectin added (K(D) = 0.85 +/- 0.37 pM). Binding was competitively inhibited by the terminal GalNAc-containing glycoprotein asialofetuin (P < 0.005). Taken together, these data provide direct evidence that the cysteine-rich region of the Gal/GalNAc lectin heavy subunit contains one or more carbohydrate-binding domains.  (+info)

Malignant Brenner tumors of the ovary and tumor markers: case reports. (7/692)

We investigated the tumor marker for malignant Brenner tumors, which had not been established because of the rarity and variable histological criteria. Representative areas of two cases of malignant Brenner tumor were investigated by means of the peroxidase-antiperoxidase method using monoclonal antibody to CA125 and CA72-4 antigen and the streptavidin-biotin immunoperoxidase complex method using monoclonal antibody to SCC antigen. Based on clinical course and immunohistochemical studies, serum CA125 and CA72-4 for Case 1 and SCC and CA72-4 for Case 2 were appropriate tumor markers for the establishment of the extent of tumor burden before treatment and to monitor the response to therapy. The discrepancy of the tumor markers of the two present cases is considered to be a reflection of the difference in the malignant component of these cases. However, serum CA72-4 was an appropriate tumor marker for both malignant Brenner tumors.  (+info)

The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. (8/692)

The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of ovarian cancer. Both markers were measured in 30 patients with proven epithelial ovarian cancer, 30 patients with benign pelvic masses and 30 normal women. CA125 and CA72-4 were measured using the luminometric immunoassay and immunoradiometric assay respectively. All patients with ovarian cancer were submitted to surgical staging and cytoreduction followed by adjuvant platinum based chemotherapy for 3-6 courses. Fixing the specificity at 95%, CA125 had a sensitivity of 76.7% at a cut-off 85 u/ml while CA72-4 had a sensitivity of 70% at a cut-off 8.5 u/ml. The combination of CA72-4 with CA125 increased the sensitivity to 95% while fixing the specificity at 95%. Among seven cases with stage I and II ovarian cancer five cases had CA125 level below 85 U/ml, three patients out of them had CA72-4 above 8.5 U/ml. CA 72-4 could reflect the residual disease following cytoreduction and could improve the detection of relapse by CA125. CONCLUSION: CA72-4 could complement the standard tumor marker CA125 both in diagnosis and follow up of patients with epithelial ovarian cancer.  (+info)

*Synthetic immunology

... structurally complex carbohydrate tumor antigen and adjuvants synthesis, immunogenic chemotherapeutic agents and chemically ... Survival times increased from 160 to 220 percent, depending on the type of tumor. Therapeutic vaccines treat and immunize ... Provenge is an adoptive cell-transfer therapy in which a patient's antigen-presenting target autologous prostate cancer tissue ... Lavars, Nick (2016-02-24). "Ordinary skin cells turned into brain tumor predators". www.gizmag.com. Gizmag. Retrieved 2016-02- ...

*Pancreatic cancer

... carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks sensitivity ... Tumors within the pancreas only (localized tumors), or with limited metastases, for example to the liver, may be removed by ... Lanreotide can slow tumor growth. If the tumor is not amenable to surgical removal and is causing symptoms, targeted therapy ... Radiotherapy may form part of treatment to attempt to shrink a tumor to a resectable state, but its use on unresectable tumors ...

*Liver cancer

... carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are ... whether due to spread of the initial tumor or formation of new tumors . Liver transplantation can also be considered in cases ... Tumor markers, chemicals sometimes found in the blood of people with cancer, can be helpful in diagnosing and monitoring the ... Removing the tumor by either surgical resection or liver transplant can be used in the treatment of hepatoblastoma. In some ...

*Liver tumor

... carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are ... Liver tumors or hepatic tumors are tumors or growths on or in the liver (medical terms pertaining to the liver often start in ... Tumor characterization is a complex process based on a sum of criteria leading towards tumor nature definition. Often, other ... Upon discovery of a liver tumor, the main issue in the workup is to determine whether the tumor is benign or malignant. Many ...

*Avadhesha Surolia

He genetically re-engineered carbohydrate specificities of lectins imparting exquisite T-antigen tumor recognizing ability to ... He discovered novel blood group and tumor antigen specific lectins and made original contribution towards elucidation of the ... "Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its ... Carbohydrate specificity generated by water bridges". Current Science. 72: 855-861. Reddy GB, Bharadwaj S; Surolia A (1999). " ...

*Cantuzumab

"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1 ... Also known as huC242 it binds the CanAg antigen. It is typically linked to one of several cytotoxic agents, yielding antibody- ... Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors ...

*List of MeSH codes (D23)

... antigens, cd30 MeSH D23.050.285.040 --- antigens, cd147 MeSH D23.050.285.050 --- antigens, tumor-associated, carbohydrate MeSH ... antigens, cd30 MeSH D23.101.840.075 --- antigens, tumor-associated, carbohydrate MeSH D23.101.840.075.050 --- antigens, cd15 ... tumor-associated, carbohydrate MeSH D23.050.550.325.050 --- antigens, cd15 MeSH D23.050.550.325.115 --- ca-15-3 antigen MeSH ... ca-19-9 antigen MeSH D23.050.285.050.225 --- ca-125 antigen MeSH D23.050.285.062 --- antigens, viral, tumor MeSH D23.050. ...

*CA-125

Yu B, Xu PZ, Wang QW, Zhou H, Zhou HX (2009). "Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen- ... cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and ... CA-125 (cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) also known as mucin 16 or MUC16 is a protein ... Boivin M, Lane D, Piché A, Rancourt C (Dec 2009). "CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian ...

*Tumor M2-PK

... ), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 724 in the diagnosis of gastrointestinal ... Tumor M2-PK can be elevated in many tumor types, rather than being an organ-specific tumor marker such as PSA. Increased stool ... September 2001). "Tumor M2 pyruvate kinase in plasma of patients with urological tumors". Tumour Biol. 22: 282-5. doi:10.1159/ ... which correlated with the tumor stage. The combination of Tumor M2-PK with the appropriate classical tumor marker, such as CEA ...

*Stomach cancer

Blood tests for tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) may be ordered, as their ... Dysphagia suggests a tumour in the cardia or extension of the gastric tumour into the esophagus. These can be symptoms of other ... Lymphomas and mesenchymal tumors may also develop in the stomach. Most of the time, stomach cancer develops in stages over ... Most stomach tumors are malignant with evidence of spread to lymph nodes or liver, making treatment difficult. Except for ...

*Thomsen-Friedenreich antigen

In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we immunized Balb/c mice ... Tumor restriction of Thomsen-Friedenreich antigen may therefore be determined either by the protein backbone or by the beta- ... Yu, Lu-Gang (2007). "The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 ... represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven ...

*Cancer immunotherapy

... known as tumour-associated antigens (TAAs); they are often proteins or other macromolecules (e.g. carbohydrates). Active ... The dendritic cells are activated in the presence of tumor antigens, which may be a single tumor-specific peptide/protein or a ... T-cells specific to a tumor antigen can be removed from a tumor sample (TILs) or filtered from blood. Subsequent activation and ... Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which ...

*CA19-9

CA 19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis (a) antigen) is a tumor marker that is ... CA 19-9 is an antigen defined by monoclonal antibody binding to CA 19-9, the tumor surface marker Sialyl-Lewis A. CA 19-9 was ... Goonetilleke KS, Siriwardena AK (April 2007). "Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in ... In patients who lack the Lewis antigen (a blood type antigen on red blood cells), which is about 10% of the Caucasian ...

*Oligosaccharide

Glycoproteins are relevant as cell-surface receptors, cell-adhesion molecules, immunoglobulins, and tumor antigens. Glycolipids ... Protein-Carbohydrate bonding is often mediated by hydrogen bonding and van der Waals forces.[citation needed] Mixed feeding of ... serves as a precursor for the A and B antigen. Therefore, a person with A blood type will have the A antigen and H antigen ... A person with B blood type will have the B and H antigen present. A person with AB blood type will have A, B, and H antigens ...

*CD69

1995). "CD 69 antigen of human lymphocytes is a calcium-dependent carbohydrate-binding protein". Biochem. Biophys. Res. Commun ... of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis ... Hamann J, Fiebig H, Strauss M (1993). "Expression cloning of the early activation antigen CD69, a type II integral membrane ... 1994). "Structure of the gene coding for the human early lymphocyte activation antigen CD69: a C-type lectin receptor ...

*Selectin

"Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis". Dis. Colon Rectum. 40 (4): 420-31. doi: ... Witz IP (2006). "Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk". ... A number of studies have shown increased expression of carbohydrate ligands on metastatic tumor, enhanced E-selectin expression ... Tumor cells exploit the selectin-dependent mechanisms mediating cell tethering and rolling interactions through recognition of ...

*LAMP1

"Role of tumor cell surface lysosome-associated membrane protein-1 (LAMP1) and its associated carbohydrates in lung metastasis ... Acevedo-Schermerhorn C, Gray-Bablin J, Gama R, McCormick PJ (Nov 1997). "t-complex-associated embryonic surface antigen ... LAMP1 expression on the surface of tumor cells has been observed for a number of different cancer types, particularly in highly ... The structure of LAMP1 correlates with differentiation and metastatic potential of tumor cells as it is thought to help mediate ...

*B3GAT1

Although the antigen is particularly common in carcinoid tumours, it is found in such a wide range of other conditions that it ... It is expressed as a carbohydrate epitope that contains a sulfoglucuronyl residue in several adhesion molecules of the nervous ... In anatomical pathology, CD57 (immunostaining) is similar to CD56 for use in differentiating neuroendocrine tumors from others ... CD57 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Human B3GAT1 genome location and B3GAT1 ...

*Kim Janda

Carbohydrate Antigen". Journal of the American Chemical Society. 124 (42): 12439-12446. doi:10.1021/ja020737j. Gao, Changshou; ... that are selective for melanoma and breast tumor cells. The Janda laboratory has also identified a scFv specific for the ... "De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods". Journal of ...

*Teratoma

"Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19 ... Teratomas belong to a class of tumors known as nonseminomatous germ cell tumor (N.S.G.C.T.). All tumors of this class are the ... These cells can develop into a frankly malignant tumor known as yolk sac tumor or endodermal sinus tumor. Adequate follow-up ... primitive neuroectodermal tumor, Wilm's tumor, desmoplastic small round cell tumor, and non-Hodgkin lymphoma. A teratoma with ...

*Derek LeRoith

... between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour ... doi:10.1016/j.ecl.2009.09.006 PMID 19944284 Biological effects of growth hormone on carbohydrate and lipid metabolism. ... doi:10.1016/j.bone.2008.12.012 PMID 19150422 Murine osteosarcoma primary tumour growth and metastatic progression is maintained ... Insulin sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Fierz Y, Novosyadlyy R, Vijayakumar ...

*Tumor marker

TPA Tumor antigen List of cancer types "Tumor markers Cancer screening". Retrieved December 28, 2013. Kilpatrick, E. S; Lind, M ... On the basis of their chemical nature tumor markers can be proteins, conjugated proteins, peptides or carbohydrates. Proteins ... Tumor markers can be produced directly by the tumor or by non-tumor cells as a response to the presence of a tumor. Although ... Diagnosis of specific tumor types, particularly in certain brain tumors and other instances where biopsy is not feasible. ...

*High endothelial venules

T cells become activated by recognising foreign antigens bound to antigen presenting cells (APC), in particular, dendritic ... The MECA-79 carbohydrate epitope decorates a family of HEV counter-receptors for L-selectin, both in mouse and human16. Another ... in mucosal HEVs and in venules of intestinal lamina propria but can be induced in nonmucosal endothelial cells by tumor ... Since antigen levels are usually low, contact in blood circulation would be unlikely. Therefore, T cells need a region where ...

*Waldenström's macroglobulinemia

Bone marrow tumour cells express the following antigen targets CD20 (98.3%), CD22 (88.3%), CD40 (83.3%), CD52 (77.4%), IgM ( ... binding water through their carbohydrate component and by their interaction with blood cells. A diagnosis of Waldenström's ... Blood tests show the level of IgM in the blood and the presence of proteins, or tumor markers, that are the key symptoms of WM ... ISBN 0-8151-8698-3. Raje N, Hideshima T, Anderson KC (2003). "Plasma Cell Tumors". In Kufe DW, Pollock RE, Weichselbaum RR, ...

*Sialyl-Lewis X

Sialyl Lewis X is also one of the most important blood group antigens and is displayed on the terminus of glycolipids that are ... Sialyl Lewis x is being used in studies to fight tumors and cancer cell growth. It has been shown that there is frequent ... Sialyl LewisX, also known as sialyl LeX or SLeX, is a tetrasaccharide carbohydrate with the sequence Neu5Acα2-3Galβ1-4[Fucα1-3] ... Sialyl Lewis x is an inflammation-associated antigen on liver cells. It becomes over expressed on diseased liver cells and can ...

*CD34

Antigens, CD34 at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... In tumors, CD34 is found in alveolar soft part sarcoma, preB-ALL (positive in 75%), AML (40%), AML-M7 (most), ... Berg EL, Mullowney AT, Andrew DP, Goldberg JE, Butcher EC (Feb 1998). "Complexity and differential expression of carbohydrate ... Hematopoietic progenitor cell antigen CD34 also known as CD34 antigen is a protein that in humans is encoded by the CD34 gene. ...
3554-90-3 - QCQYVCMYGCHVMR-AAZUGDAUSA-N - Thomsen-Friedenreich antigen - Similar structures search, synonyms, formulas, resource links, and other chemical information.
The abnormal glycans expressed by cancer cells, known as tumor-associated carbohydrate antigens (TACAs), are useful epitopes for the development of therapeutic cancer vaccines,1,2 as they are abundant and exposed on the cancer cell surface and thereby easy targets for the human immune system. Among many TACAs identified so far,3,4 the globo H antigen, which is a rather tumor-specific hexasaccharide antigen, is especially attractive. Globo H was first discovered in conjugation with lipids on human breast cancer cell MCF-7,5,6 and later on was also found on a variety of other epithelial tumors, such as lung, colon, ovarian, and prostate cancer.7 As a result, globo H-based anticancer vaccines can be broadly useful for treating different tumors, and globo H has become a hot topic for synthetic studies and cancer vaccine design.8,9 However, similar to most carbohydrate antigens, globo H itself is poorly immunogenic and T cell-independent,10,11 while T cell-mediated immunity, which means antibody ...
The tumor-specific Thomsen-Friedenreich antigen (TFα, CD176) is an attractive target for a cancer vaccine, especially as TF-directed antibodies play an important role in cancer immunosurveillance. However, synthetic TF vaccines have not overcome the
The Ca antigen, which can be detected in a wide range of malignant human tumours by means of the Cal antibody, is a glycoprotein of the mucin type. At least 95% of the carbohydrate is 0-glycosidically linked to the polypeptide which contains high proportions of glycine, serine and glutamic acid. The carbohydrate has a very simple structure: it is composed almost entirely of tetra- tri- and disaccharides having the general formula (NeuNac)n leads to [Gal leads to GalNac] alpha leads to, where n = 0, 1 or 2. In many malignant cell lines, the antigen is produced constitutively in vitro; but in one that has been examined, its synthesis can be induced by high concentrations of lactate. Evidence is presented for the view that a primary function of this glycoprotein is to shield the cells that produce it from hydrogen ion concentrations outside of the physiological range. The presence of the Ca antigen in malignant tumours may thus be a reflection of metabolic conditions that are known to be characteristics of
PURPOSE: Sialyl Tn (STn) antigen is a cancer-associated carbohydrate antigen expressed in cancers of the digestive tract. We compared the proportion of specimens of flat-type colorectal cancers...
Carbohydrate antigens recognized by "natural" or preformed and elicited antibodies are central to transplantation/transfusion rejection across ABO blood group and species (xenotransplantation) barriers and are also promising candidates for cancer immunotherapy (Ramsland 2005). The key carbohydrate determinants (epitopes) recognized by antibodies are synthesized by a series of intracellular glycosyltransferases and are expressed on the surface of cells as glycolipids and glycoproteins. Often the minimal carbohydrate epitopes are located at the terminal end of more complex oligosaccharide chains, which result in these epitopes being displayed at a wide range of surface densities and contexts (e.g., glycolipids or glycoproteins). For example, many tumor-associated carbohydrate antigens are broadly expressed at very high densities on the cell surface of primary and metastatic tumors, but the same carbohydrates occur at much lower levels and are typically restricted to a few cell types in healthy ...
Sialyl Lewis A (sLeA, also known as CA19-9), a tetrasaccharide selectively and highly expressed on advanced adenocarcinomas including colon, stomach, and pancreatic cancers, has long been considered as an attractive target for active and passive vaccination. While progress in antibodies targeting tumor-associated protein antigens resulted in an impressive array of therapeutics for cancer treatment, similar progress in exploiting tumor-associated carbohydrate antigens, such as sLeA, has been hampered by the lack of a detailed understanding of the singular characteristics of these antigens. We have addressed this issue by analyzing antibodies derived from patients immunized with an sLeA/KLH vaccine. These antibodies were engineered to mediate tumor clearance in vivo in preclinical models through Fc-FcγR interactions. However, in contrast to protein antigens in which hFcγRIIIA engagement was both necessary and sufficient to mediate tumor clearance in both preclinical and clinical settings, a ...
Sialyl-Tn antigen (STn) is a short O-glycan containing a sialic acid residue a2,6-linked to GalNAca-O-Ser/Thr. The biosynthesis of STn is mediated by a specific sialyltransferase termed ST6GalNAc I, which competes with O-glycans elongating glycosyltransferases and prevents cancer cells from exhibiting longer O-glycans. While weakly expressed by fetal and normal adult tissues, STn is expressed by more than 80% of human carcinomas and in all cases, STn detection is associated with adverse outcome and decreased overall survival for the patients. Because of its pan-carcinoma expression associated with an adverse outcome, an anti-cancer vaccine, named Theratope, has been designed towards the STn epitope. In spite of the great enthusiasm around this immunotherapy, Theratope failed on Phase III clinical trial. However, in lieu of missing this target, one should consider to revise the Theratope design and the actual facts. In this review, we highlight the many lessons that can be learned from this failure from
Patterns of glycosylation are important in cancer, but the molecular mechanisms that drive changes are often poorly understood. The androgen receptor drives prostate cancer (PCa) development and progression to lethal metastatic castration-resistant disease. Here we used RNA-Seq coupled with bioinformatic analyses of androgen-receptor (AR) binding sites and clinical PCa expression array data to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in PCa cells. ST6GalNAc1 encodes a sialytransferase that catalyses formation of the cancer-associated sialyl-Tn antigen (sTn), which we find is also induced by androgen exposure. Androgens induce expression of a novel splice variant of the ST6GalNAc1 protein in PCa cells. This splice variant encodes a shorter protein isoform that is still fully functional as a sialyltransferase and able to induce expression of the sTn-antigen. Surprisingly, given its high expression in tumours, stable expression of ST6GalNAc1 in PCa cells reduced formation
Rahman, A F. and Longenecker, B M., "A monoclonal antibody specific for the thomsen-friedenreich cryptic t antigen." (1982). Subject Strain Bibliography 1982. 3746 ...
My laboratory, RPCI based for the first 9 years, and now at UB for the last 13 years, has had an emphasis on tumor associated carbohydrate antigens, and recently has been involved in 2 patent applications, "Use of anti-TF antibody to block metastasis of TF- antigen bearing tumors" (K R Olson, principle inventor of JAA-F11 monoclonal antibody), and "Carbohydrate Antigen-Nanoparticle Conjugates and Methods for Inhibiting Metastasis in Cancer" (K R Olson, co-inventor). Thomsen-Friedenreich antigen (TF-Ag) is a tumor associated antigen that is exposed in many types of carcinoma cells including breast, prostate, colon, and bladder. My laboratory recently reported results from in vitro and in vivo studies that show the anti-metastatic effect of treatment with JAA-F11 antibody to TF- Ag on the mouse metastatic breast carcinoma 4T1 cells.. The anti-TF antibody metastasis work was just published in Neoplasia (vol 8 number 11) and is the featured article, with cover art. A portion of this work involved ...
Springer, G F. and Desai, P R., "Cross-reacting carcinoma-associated antigens with blood group and precursor specificities." (1977). Subject Strain Bibliography 1977. 2171 ...
Polyagglutination refers to red blood cells that agglutinate upon exposure to almost all human sera, but not to autologous serum or the sera of newborns. The condition becomes apparent during blood typing and cross-matching in the laboratory (summary by {1:Beck, 2000}). Tn polyagglutination syndrome is an acquired clonal disorder characterized by the polyagglutination of red blood cells by naturally occurring anti-Tn antibodies following exposure of the Tn antigen on the surface of erythrocytes. Only a subset of red cells express the antigen, which can also be expressed on platelets and leukocytes. This condition may occur in healthy individuals who manifest asymptomatic anemia, leukopenia, or thrombocytopenia; however, there is also an association between the Tn antigen and leukemia or myelodysplastic disorders. The Tn antigen is an incompletely glycosylated membrane glycoprotein with an exposed N-acetylgalactosamine residue. The Tn antigen results from inactivation of C1GALT1C1, which encodes ...
Activation of an aberrant glycosylation pathway in cancer cells can lead to expression of the onco-foetal sialyl-Tn (sTn) antigen. STn is a truncated O-glycan containing a sialic acid α-2,6 linked to GalNAc α-O-Ser/Thr and is associated with an adverse outcome and poor prognosis in cancer patients. The biosynthesis of the sTn antigen has been linked to the expression of the sialytransferase ST6GalNAc1, and also to mutations in and loss of heterozygosity of the COSMC gene. sTn neo- or over-expression occurs in many types of epithelial cancer including gastric, colon, breast, lung, oesophageal, prostate and endometrial cancer. sTn is believed to be carried by a variety of glycoproteins and may influence protein function and be involved in tumour development. This review discusses how the role of sTn in cancer development and tumour cell invasiveness might be organ specific and occur through different mechanisms depending on each cancer type or subtype. As the sTn-antigen is expressed early in
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
... is ordered to monitor pancreatic, liver, gastrointestinal, and colorectal malignancies.
Carbohydrate Antigen (CA) 19-9 (LabCorp). Get know how much does lab test cost. Direct access testing with or without insurance.
Amines, aminooxy (also known as oxylamine), hydrazide, azide, alkyne, BCN, and tyramide reactive dyes, as well as dye free acids, are generally stable in aqueous solution when stored at -20°C for 6-12 months or longer, as long as no compounds are present that may react with the dyes functional group. See the product information sheets for specific reactive dyes more information.. Coelenterazines and D-luciferin. Coelenterazines are stable in solid form when stored as recommended; they are not stable in aqueous solution. Concentrated coelenterazine stock solutions (typically 1-100 mg/mL) should be prepared in ethanol or methanol; do not use DMSO or DMF to dissolve coelenterazines, because these solvents will oxidize the compounds. Ethanol or methanol stocks of coelenterazine can be stored at -20°C or below for six months or longer; alcohol stocks may evaporate during storage, so use tightly sealing screw cap vials and wrap the vials with Parafilm for long term storage. Propylene glycol also ...
Cells possess Ca antigen as defined by the Ca1 antibody. The Ca antigen has been shown to be absent in non-malignant human cell strains and is considered to be a marker linked with malignancy. Island cell growth will degenerate if left more than 9 days between passages ...
Active immunization of cancer patients to induce de novo functional anti-tumor immune responses is an alternative/complementary approach to chemotherapy. Tumor vaccines hold the potential to deliver durable, specific and systemic anti-tumor responses in patients. We have been developing active vaccination strategies targeting tumor associated carbohydrate antigens (TACAs) using carbohydrate mimetic peptides. TACAs play roles in initiation and metastasis of cancer and considered as common targets shared by many tumor types. TACA support cell survival that can be interrupted by anti-carbohydrate antibodies. An early-phase 3+3 clinical trial was conducted to evaluate the feasibility, safety and immune functionality of a carbohydrate mimetic-peptide (CMP) vaccine referred to as P10s, which can induce TACA reactive, proapoptotic antibodies. In this trial a dose-escalation trial of vaccine plus adjuvant was conducted in two cohorts of 3 subjects each. Patients were restricted to females of all races ...
We are an interdisciplinary research group at the interface of carbohydrate research and immunology. Our objective is to explore treatment of and protection from infectious diseases and cancer by understanding key molecular and cellular interactions between the components of the immune system and carbohydrate antigens associated with microbes or cancers.. Our research program is directed at: delineating immune mechanisms involved in carbohydrate-mediated adaptive immune response, and designing, synthesizing and testing vaccine targets against model pathogens and cancers. Our research approach involves: (1) identification of the molecular interactions involved in uptake, processing and presentation of carbohydrate antigens by the antigen presenting cells (APCs), (2) isolation and characterization of T cells and their epitopes generated from model carbohydrate antigens, (3) understanding the basis for cellular and humoral immune responses induced by carbohydrate presentation and recognition that ...
Synthesis and Vaccine) appraises currently So the dimensione of a 3ann. Gebiet otherwise are from ten to thirty, or rather more Banne. Stendortfuhrer( Garrison Commander).
Principal Investigator:IBAYASHI Yukihiro, Project Period (FY):1993 - 1994, Research Category:Grant-in-Aid for General Scientific Research (C), Research Field:Cerebral neurosurgery
This glycoprotein is a mucinous carbohydrate antigen product of the MUC1 gene expressed on various adenocarcinomas, especially breast. It is a high molecular weight (300-450 kDa) 1 polymor... ...
CA50, 0.5 mg. Cancer antigen 50 (CA50), a carcinoma associated carbohydrate antigen, has been found to be elevated in the blood of patients with colorectal cancer and other malignancies.
Authors: Ju, Tongzhong , Aryal, Rajindra P. , Kudelka, Matthew R. , Wang, Yingchun , Cummings, Richard D. Article Type: Research Article Abstract: The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser/Thr (Tn antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Galβ1-3GalNAcα1-O-Ser/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 β3-galactosyltransferase or C1GalT). Formation …of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by Cosmc on the X-chromosome (Xq24 in humans, ...
Thomsen-Friedenreich antigen (Galbeta1-3GalNAc), generally known as T-antigen, is expressed in more than 85% of human carcinomas. Therefore, proteins which specifically bind T-antigen have potential diagnostic value. Jacalin, a lectin from jack fruit (Artocarpus integrifolia ) seeds, is a tetramer of molecular mass 66 kDa. It is one of the very few proteins which are known to bind T-antigen. The crystal structure of the jacalin-T-antigen complex has been determined at 1.62 A° resolution. The interactions of the disaccharide at the binding site are predominantly through the GalNAc moiety, with Gal interacting only through water molecules. They include a hydrogen bond between the anomeric oxygen of GalNAc and the pie electrons of an aromatic side-chain. Several intermolecular interactions involving the bound carbohydrate contribute to the stability of the crystal structure. The present structure, along with that of the Me-alpha-Gal complex, provides a reasonable qualitative explanation for the ...
Beli RACING ENGINE OIL FULLY SYNTHETIC 10W-60 HYRAX OIL di Ampang,Malaysia. -PROMOTION RACING ENGINE OIL FULLY SYNTHETIC 10W-60 HYRAX OIL -PROVEN AND TEST ON RACING TRACK HYRAX OIL Formulate specifically for top performance ~Reduced fr Chat untuk Membeli
Carbohydrate antigen (CA19-9) is a protein that is found in very small amounts on the surface of certain cancer cells. It may be found in the blood when it is shed by tumour cells. It is also found in trace amounts in the pancreas, liver, gall bladder and lungs of healthy adults.
O-Glycopeptide structural studies, specifically related to Tn antigen, have pointed to intramolecular interactions between the GalNAc and the peptide backbone via H-bonding. Although molecular mimics to Tn antigen have been the target of numerous synthetic and immunological studies, many have not considered the established conformational preferences. Initiatives for the development of improved mimetic design are proposed here. Specifically a metabolically robust C-linkage is designed, yet one with a pendant hydroxyl to maintain the key H-bonding network to properly orient the glycan with respect to the peptide. We herein propose to synthesize pure, robust mimics of Tn antigen, with conformational realism, as they may be presented from the backbone of biomedically relevant peptides (such as MUC1) and to compare these mimics with Tn antigen itself, by NMR and molecular dynamics simulations for clarification of the essential structural features necessary to maximize biological activity. The most ...
Carbohydrate antigen (CA19-9) is a protein that is found in very small amounts on the surface of certain cancer cells. It may be found in the blood when it is shed by tumour cells. It is also found in trace amounts in the pancreas, liver, gall bladder and lungs of healthy adults.
TY - JOUR. T1 - Enhanced self-association of mucins possessing the T and Tn carbohydrate cancer antigens at the single-molecule level. AU - Haugstad, Kristin E.. AU - Gerken, Thomas A.. AU - Stokke, Bjørn T.. AU - Dam, Tarun K.. AU - Brewer, C. Fred. AU - Sletmoen, Marit. PY - 2012/5/14. Y1 - 2012/5/14. N2 - Mucins are linear O-glycosylated glycoproteins involved in inflammation, cell adhesion, and tumorigenesis. Cancer-associated mucins often possess increased expression of the T (Galβ1,3GalNAcαThr/Ser) and Tn (GalNAcαThr/Ser) cancer antigens, which are diagnostic markers for several cancers, including colon cancer. We have used AFM based single-molecule forced unbinding under near physiological conditions to investigate the self-interactions between porcine submaxillary mucin (PSM) as well as between PSM analogs possessing various carbohydrates including the T- and Tn-antigen. Distributions of unbinding forces and corresponding force loading rates were determined for force loading rates ...
MilliporeSigma today announced Millistak+® HC Pro, the first portfolio of high- capacity, fully synthetic depth filters for non-treated Chinese Hamster Ovary (CHO) harvest clarification and downstream filtration applications.
Fully Synthetic Chain Lube - protects chains from wear and corrosion. Initialy a thin free-flowing lubricant when sprayed searches and penetrates into the chain links and rollers.
Fasting Required: No Specimen: Blood Results: 1-2 Business Days Description: Cancer antigen (CA) 27.29 is used to monitor metastatic carcinoma of the...
Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
Publication Details (including relevant citation information): Wilson, R.M., Warren, J.D., Ouerfelli, O., Danishefsky, S.J. 989 258-292
Danish drugmaker Pharmexa says it plans to file for approval to start a second Phase III trial of its peptide anticancer vaccine GV1001 in pancreatic cancer within the next few weeks. - News - PharmaTimes
[button size=small text=MSDS & Datasheet link=/wp-content/uploads/media/BCDatasheets_C_10.26/BXXXX/B-3501-2.pdf]Anti-Tn Salvia sclarea Lectin -SS
TY - JOUR. T1 - Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. T2 - A pooled analysis of 6 prospective trials. AU - Bauer, Todd M.. AU - El-Rayes, Bassel F.. AU - Li, Xiaobai. AU - Hammad, Nazik. AU - Philip, Philip A.. AU - Shields, Anthony F.. AU - Zalupski, Mark M.. AU - Bekaii-Saab, Tanios. PY - 2013/1/15. Y1 - 2013/1/15. N2 - Background: Carbohydrate antigen 19-9 (CA19-9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19-9 serum levels and its role in the clinical management of patients with pancreatic cancer. Methods: Individual patient data from 6 prospective trials evaluating gemcitabine-containing regimens from 3 different institutions were pooled. CA19-9 values were obtained at baseline and after successive cycles of treatment. The objective of this study was to correlate a decline in CA19-9 with outcomes while ...
Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly Xinjin Gu,1 Rong Liu2 1Department of Hepatobiliary Surgery, Chinese People’s Liberation Army General Hospital and Hainan Branch, Sanya, 2Department of Hepatobiliary and Pancreatic Surgical Oncology, Chinese People’s Liberation Army General Hospital, Beijing, People’s Republic of China Objective: The current study was designed to analyze the value of 18F-FDG positron emission tomography/computed tomography (PET/CT) combined with carbohydrate antigen 19-9 (CA19-9) in differentiating pancreatic carcinoma (PC) from chronic mass-forming pancreatitis (CMFP) in Chinese elderly. Methods: As it is impossible to differentially diagnose PC from CMFP, 60 participants older than 65 years with focal pancreatic lesions were scanned by 18F-FDG PET/CT and their CA19-9 levels were tested. Diagnoses of all participants were
The World Health Organisation in 1997 recognised the need for the development of new drugs to combat the imminent threat of mass infection by multi-drug resistant strains of pathogenic micro-organisms that spread diseases such as tuberculosis (TB). With this in mind, the work covered in this thesis focused on the preparation of novel carbohydrate-based compounds as potential anti-bacterial agents, in particular targeted to mycobacterial infection. An essential cell wall structural component of various mycobacteria (including M. tuberculosis) is the galactofuranose (Galf) residue, which forms part of the polysaccharide connection between the mycolic acids and the peptidoglycan layer. Interference with the incorporation of Galf into this polysaccharide was expected to compromise the physical integrity of the bacterial cell wall leading to cell death. With minimal projected side-effects, owing to the lack of Galf residues in mammalian systems, hydrolytically-stable Galf analogues were selected as ...
Artur » Lista över publikationer » Tsuji-Wacker-Type Oxidation beyond Methyl Ketones: Reacting Unprotected Carbohydrate-Based Terminal Olefins through the "Uemura System" to Hemiketals and α,β-Unsaturated Diketones ...
Praxis Pharmaceuticals and Fairchild International Corporation had a joint development agreement covering the carbohydrate-based anti-inflammatories being
Alt. Names/Synonyms: ACSTD1; Adenocarcinoma-associated antigen; carcinoma-associated antigen GA733-2; Cell surface glycoprotein Trop-1; CO-17A; CO17-1A; DIAR5; EGP; EGP-2; EGP314; EGP34; EGP40; Ep-CAM; EPCAM; Epithelial cell adhesion molecule; Epithelial cell surface antigen; Epithelial glycoprotein; Epithelial glycoprotein 314; ESA; GA733-2; hEGP-2; hEGP314; HNPCC8; human epithelial glycoprotein-2; KS 1/4 antigen; KS1/4; KSA; M1S2; M4S1; Major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; TACST-1; TACSTD1; TROP1; Tumor-associated calcium signal transducer 1 ...
TACAS is a forum for researchers, developers and users interested in rigorously based tools and algorithms for the construction and analysis of systems. The conference serves to bridge the gaps between different communities that share common interests in, and techniques for, tool development and its algorithmic foundations. The research areas covered by such communities include but are not limited to formal methods, software and hardware verification, static analysis, programming languages, software engineering, real-time systems, communications protocols, and biological systems. The TACAS forum provides a venue for such communities at which common problems, heuristics, algorithms, data structures and methodologies can be discussed and explored. In doing so, TACAS aims to support researchers in their quest to improve the utility, reliability, flexibility and efficiency of tools and algorithms for building systems. Tool descriptions and case studies with a conceptual message, as well as ...
IMPFSTOFFE + VAKZINE (PHARMAZIE); OBERFLÄCHENANTIGENE (IMMUNOLOGIE); ORGANISCHE SYNTHESE (CHEMIE); PROTEIN-MIKROARRAY-TECHNOLOGIE (MOLEKULARGENETISCHE TECHNIKEN); VACCINES (PHARMACY); SURFACE ANTIGENS (IMMUNOLOGY); ORGANIC SYNTHESIS (CHEMISTRY); PROTEIN MICROARRAY TECHNOLOGY (MOLECULAR GENETIC TECHNIQUES ...
Certificates of Analysis are associated not only with a product, but also with a specific lot of that product. For a given product, there may be several Certificates of Analysis, especially if it is an older product line and has had several lots produced over the years. Using the Certificate of Analysis search tool, you can enter the catalog number and lot/control number for the specific product you have on hand and download the exact Certificate of Analysis you need.. ...
TAG72, 0.1 mg. Tumor-associated glycoprotein (TAG) 72 is a tumor marker, identified and characterized using two different monoclonal antibodies B72.3 and CC49.
Gentaur molecular products has all kinds of products like :search , Abfron \ Anti-TF, Mouse Monoclonal to TF, Isotype IgG1, Host Mouse \ LF-MA42457 for more molecular products just contact us
Using a stepwise approach which combined genome-wide expression profiling and TaqMan real-time PCR, we could identify five new tumor markers for the monitoring of MRD in AML. In combination with WT1 and PRAME, these markers should allow a more sensitive and specific monitoring of MRD than WT1 or PRAME alone. Combining all seven markers, 28 patients (54%) expressed at least one gene at a level of ,100 units. In 18 patients (35%), the level of the strongest marker ranged between 10 and 100 units. In only six patients (11%) were all marker genes expressed at levels of ,10 units.. Prospective studies are needed to determine what level of overexpression of a gene is necessary for a clinically useful monitoring of MRD. In patients B, E, and G (Fig. 3), the pending relapse was indicated by genes that were expressed with ,100 units in the leukemic cells at the time of relapse. The total amount of RNA in leukemic cells is higher than in most healthy cells. Furthermore, the leukemic cells are enriched by ...
A carbohydrate antigen found on cells of E. coli and other species prompts a potent immune response against malaria-causing parasites in mice.. 1 Comment. ...
Supergrind Plus is a fully synthetic grinding fluid offering exceptional performance and extended sump life in most grinding operations.
Research Interest. We strive to exploit the power of synthetic small molecules for development of tools for glycomics/glycoproteomics, carbohydrate-based inhibitors, and synthetic oligosaccharide-based conjugate vaccines. Using chemical biology approaches we are investigating structure-function relationships of glycoforms of leukocyte antigens, engineering of glycans in central nervous system (CNS), and glycopeptidomimetics based anti-metastatic agents.. Group Members. Ms. Surbhi Goswami, Ms. Vandita Dwivedi, Ms. Pratima Saini, Ms. Ahana Addhya, Ms. Anam Tasneem, Mr. Shubham Parashar, and Ms. Charu Chauhan. Technical Support - Ms. Archana Ranjan, Mr. Mohd. Aslam, Mr. P. Rajkumar. Past Members - Dr. Kavita Agarwal, Dr. Asif Shajahan, Dr. Syed Meheboob Ahmed, Dr. Rachna Kaul, Ms. Monika Garg, Ms. Deepshikha Singh, Ms. Priti Singh, Ms. Hemaswasthi, Mr. Saroj Kumar Jha, Mr. Sebanta (Sanjay) Pokhrel, Mr. Arnob Nandi.. Summary of Research. We are interested in the investigation of the ...
Carbohydrate recognition is central to many, perhaps most, microbial infection events - bacterial, fungal, viral, parasite. We are working towards better understanding of these binding events so that we can exploit them in a diagnostic context or address them by intervention through diet, with small molecule therapeutics or carbohydrate-based vaccines. Translational aspects of this work is being taken on through our spin-out company, Iceni Diagnostics. ...
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information regarding survival of patients with metastatic PC. Case Reports: We report the clinical course of 2 patients with metastatic PC who underwent palliative chemotherapy with gemcitabine. Both patients showed a significant elevation of pretreatment CA 19-9 levels (7,505 and 150,000 U/ml, respectively), however, subsequently they experienced a highly significant reduction (, 90%) of CA 19-9 kinetics under gemcitabine chemotherapy. A good disease control and a clinical benefit response were achieved in both patients. Time to tumor progression was 30 weeks and 28 weeks, overall survival 14 months and 11 months, respectively. Conclusion: These data indicate that CA 19-9 kinetics under chemotherapy may possibly serve as a useful surrogate marker for time to ...
Cancer treatment vaccines are designed to treat cancers that have already developed rather than to prevent them in the first place. Cancer treatment vaccines contain cancer-associated antigens to enhance the immune systems response to a patients tumor cells. The cancer-associated antigens can be proteins or another type of molecule found on the surface of or inside cancer cells that can stimulate B cells or killer T cells to attack them.. Some vaccines that are under development target antigens that are found on or in many types of cancer cells. These types of cancer vaccines are being tested in clinical trials in patients with a variety of cancers, including prostate, colorectal, lung, breast, and thyroid cancers. Other cancer vaccines target antigens that are unique to a specific cancer type (7-14). Still other vaccines are designed against an antigen specific to one patients tumor and need to be customized for each patient. The one cancer treatment vaccine that has received FDA approval, ...
Marine microorganisms have evolved for millions of years to survive in the environments characterized by one or more extreme physical or chemical parameters, e.g., high pressure, low temperature or high salinity. Marine bacteria have the ability to produce a range of biologically active molecules, such as antibiotics, toxins and antitoxins, antitumor and antimicrobial agents, and as a result, they have been a topic of research interest for many years. Among these biologically active molecules, the carbohydrate antigens, lipopolysaccharides (LPSs, O-antigens) found in cell walls of Gram-negative marine bacteria, show great potential as candidates in the development of drugs to prevent septic shock due to their low virulence. The structural diversity of LPSs is thought to be a reflection of the ability for these bacteria to adapt to an array of habitats, protecting the cell from being compromised by exposure to harsh environmental stress factors. Over the last few years, the variety of structures of core
NVP-BEP800 is a fully synthetic, orally bioavailable inhibitor of Hsp90 with IC50 value of 58nM [1].NVP-BEP800 binds to the N-terminal ATP-binding pocket of Hsp90. In a competitive binding fluorescence polarization assay, NVP-BEP800 inhibits Hsp90β with I
Abstract Background The lack of sufficient specificity and sensitivity among conventional cancer biomarkers, such as prostate specific antigen (PSA) for prostate cancer has been widely recognized after several decades of clinical implications. Autoantibodies (autoAb) among others are being extensively investigated as potential substitute markers, but remain elusive. One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA). Methods To circumvent preparation of phage lysates and purification of recombinant proteins, we identified B cell epitopes from a number of previously defined prostate cancer-associated antigens (PCAA). Peptide epitopes from cancer/testis antigen NY-ESO-1, XAGE-1b, SSX-2,4, as well as prostate cancer overexpressed antigen AMACR, p90 autoantigen, and LEDGF were then conjugated with seroMAP microspheres to allow multiplex measurement of autoAb present in serum samples. ...
This 13th best practice review examines tumour marker requesting primary care situations. The review is presented in question-answer format, referenced for each question. This review considers carcinoembryonic antigen carbohydrate antigen 15-3 (Ca15-3) and carbohydrate antigen 19-9 (Ca19-9). The recommendations represent a précis of guidance found using a standardised literature search of national and international guidance notes, consensus statements, health policy documents and evidence-based medicine reviews, supplemented by MEDLINE EMBASE searches to identify relevant primary research documents. They will be updated periodically to take account of new information. ...
Recent clinical success of HPV (including therapeutic) vaccines for prevention and checkpoint inhibition (proving that immunity can inhibit cancer growth) for therapy has generated tremendous enthusiasm for non-viral vaccine immunoprevention. The immune-checkpoint inhibitors (e.g., targeting CTLA-4 or PD-1), which act on previously induced T cells, are producing durable remissions in some patients with metastatic, previously treated cancers. Their utility in prevention, however, is limited by their serious autoimmune toxicities. Furthermore, it is not clear that these checkpoint signals are important in early TME. Vaccines are an immune approach that is broadly available, specific, cost-effective, and work best in immunocompetent individuals. Vaccines targeting cancer-associated antigens have been studied extensively over the last 30 years in thousands of patients and have been shown to have a very favorable safety profile setting the stage for prevention vaccines, and limited dosing should ...
199PC : As an adjunct in the assessment of pancreatic cysts, when used in conjunction with carcinoembryonic antigen, amylase, imaging studies and cytology
About 5 years ago I was diagnosed with inflammatory breast cancer. I have had several rounds of chemotheapy; the turmor responded well to the chemo to shrink it. I had a modified radical mastectomy wit...
.Flap disc 115 mm.22.23 mm.60.Highly tear-resistant cotton fabric (type YX)..Zirconia with fully synthetic resin bond..Glass-fibre backing pad.straight version. |.Bore diameter mm: 22,23 ..AC grey..Zirconia with fully synthetic resin bond. Glass-fibre backin..Specification: 115 mm, 22.23 mm, 60 .
molecular chaperone thought to be required for expression of active T-synthase, the only enzyme that galactosylates the Tn antigen (GalNAcalpha1-Ser/Thr-R) to form core 1 Galbeta1-3GalNAcalpha1-Ser/Thr (T antigen) during mucin type O-glycan biosynthesis ...
1-(beta-D-Galactopyranosyl-1-deoxy-1-iminomethyl)-2-hydroxynaphthalene (L-1), possessing an ONO binding core, was found to be selective for Cu2+ ions in N-[2-hydroxyethyl] piperazine-N-[2-ethanesulfonic acid] buffer, at concentrations ,= 580 ppb, at physiological pH by eliciting switch-on behavior, whereas the other ions, viz., Mg2+, Ca2+, Mn2+, Fe2+, Co2+, Ni2+, Zn2+, and Cd2+, caused no significant change in the fluorescence. Whereas the binding characteristics were ascertained by absorption spectroscopy, the species formed were shown by Q-TOF ES MS ...
A Cancer Antigen CA 15-3 test can help monitor people who have been diagnosed with breast cancer. Order lab testing from Request A Test for affordable pricing and quick turnaround.
Blog on anti-TF antibody product: The TF tf (Catalog #MBS710050) is an Antibody produced from Rabbit and is intended for research purposes ...
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer ...
V!NCENT writes with news that researchers at Tel Aviv University have replaced a synaptic microcircuit inside a rats cerebellum with a fully synthetic version, while maintaining proper functioning. The targeted area of the rats brain involved its ability to blink its eyes in response to particular...
V!NCENT writes with news that researchers at Tel Aviv University have replaced a synaptic microcircuit inside a rats cerebellum with a fully synthetic version, while maintaining proper functioning. The targeted area of the rats brain involved its ability to blink its eyes in response to particular...
The use of biomarkers for the detection of fungal infections is of interest to complement histopathological and culture methods. Could chemically synthesized Galactofuranose antigens, reviewed in this paper, be used for the synthesis of artificial carbohydrate-based antigens and in diagnosis? ...
The Lens serves almost all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.
BACKGROUND: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown. METHODS: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376sT and HT1376T , that express, respectively, either the sT or the T antigens ...
Background: Treatments that generate T cell-mediated immunity to a patients unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manufacturing processes are especially sought after. Here we report that AGI-134, a glycolipid-like small molecule, can be used for coating tumor cells with the xenoantigen Galalpha1-3Galbeta1-4GlcNAc (alpha-Gal) in situ leading to opsonization with pre-existing natural anti-alpha-Gal antibodies (in short anti-Gal), which triggers immune cascades resulting in T cell mediated anti-tumor immunity. Methods: Various immunological effects of coating tumor cells with alpha-Gal via AGI-134 in vitro were measured by flow cytometry: (1) opsonization with anti-Gal and complement, (2) antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells, and (3) phagocytosis and antigen cross-presentation by antigen presenting cells (APCs). A viability kit was used to test AGI
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai Meng,1–3,* Si Shi,1–3,* Chen Liang,1–3,* Dingkong Liang,1–3 Wenyan Xu,1–3 Shunrong Ji,1–3 Bo Zhang,1–3 Quanxing Ni,1–3 Jin Xu,1–3 Xianjun Yu1–3 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%–60% of patients with pancreatic cancer. Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Materials and methods: The MEDLINE, EMBASE, and Web of Science databases were
The Yarema Lab uses chemical biology, molecular and cell biology, and materials science methods to study and manipulate glycosylation. The goal of our research is to better understand human disease while furthering carbohydrate-based therapies. Our laboratorys research goals are to (1) Develop sugar analogs into viable and versatile drug candidates, (2) Apply metabolic glycoengineering to tissue engineering and stem cell research, (3) Use non-invasive magnetic stimuli to probe the effects of glycoengineering (and also to treat neurological disorders), and (4) Extend our sugar-based drug candidates into animal models and the clinic. Research Areas: carbohydrate-based therapies, chemical biology, stem cells, cell biology, materials science, neurological disorders, molecular biology ...
someWebGeek writes From PhysOrgs Taking biofuel from forest to highway, University of British Columbia biofuel expert Jack Saddler says, we will become less dependent on fossil fuels and will become more dependent on fuels made from the sugars and chemicals found in plants. Nothing too new the...
Quick, H. and Waller, L.A. (2018). "Using spatiotemporal models to generate synthetic data for public use." Spatial Spatio-temporal Epidemiol., 27, 37-45.. Quick, H., Holan, S.H., and Wikle, C.K. (2018). "Generating partially synthetic geocoded public use data with decreased disclosure risk using differential smoothing." J. Roy. Statist. Soc., Ser. A (Statistics in Society), 181, 649-661. Quick, H., Waller, L.A., and Casper, M. (2018). "A multivariate space-time model for analyzing county-level heart disease death rates by race and sex." J. Roy. Statist. Soc., Ser. C (Applied Statistics), 67, 291-304.. Quick, H., Waller, L.A., and Casper, M. (2017). "Multivariate spatiotemporal modeling of age-specific stroke mortality." Ann. Appl. Stat, 11, 2170-2182.. Quick, H., Holan, S.H., Wikle, C.K., and Reiter, J.P. (2015). "Bayesian marked point process modeling for generating fully synthetic public use data with point-referenced geography." Spatial Statistics, 14, 439-451.. Quick, H., Carlin, B.P., and ...
Free Online Library: France - CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology)
Tumor marker je taková sloučenina, jejíž koncentrace v séru se výrazně mění (obvykle stoupá) při přítomnosti určitých maligních nádorů a případně závisí na počtu nádorových buněk. Tumor markerů je celá řada, nejsou stoprocentně spolehlivé a hodí se spíše k pomocné diagnostice, či k hodnocení efektu probíhající léčby ...
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
identification of stromal factors important for bcc tumorigenesis. to identify factors produced by tumor-associated stromal cellsthat contribute to the initiation
This study compared the sensitivity and specificity of CA 50 and CA 19-9 as serum tumour markers for pancreatic cancer. One hundred and seventy one subjects were evaluated: 50 healthy controls, 50 patients with pancreatic carcinoma and 71 patients with chronic pancreatitis. Eighty per cent of the pancreatic cancer patients had raised CA 19-9 serum levels and 82% had raised CA 50 serum levels. In the group of patients ith chronic pancreatitis, false positive tests occurred in 8.4% for CA 19-9 and 11.3% for CA 50. For both markers the serum level showed a severe elevation in the advanced stage of cancer disease. Despite the good sensitivity and specificity of CA 50 as a serum tumour marker for pancreatic carcinoma, no major advantage was found compared to CA 19-9. Moreover, if the CA 50 cut-off, level is raised to 85 U/ml to exclude overlap with chronic pancreatitis, sensitivity falls sharply to 46% compared with 72% for CA 19-9 when a 100 U/ml cut-off level is used.. ...
Blood samples are collected and analyzed for routine chemistry, cytokines, chemokines, and some instances circulating tumor cells, including response to multiple lung cancer-associated antigens by IFN-γ ELISPOT CD8+ assay; CEA by CD4 class II assay; lung tumor-associated antigens by in vitro proliferation assays; regulatory T-cell (Treg) phenotype by flow cytometry; and Treg function.. Subjects complete the Lung Cancer Symptom Scale quality of life questionnaire at baseline, on the days of treatment, 30 days after completion of study treatment, and then every 3 months for 1 year.. After completion of study treatment, subjects are followed every 3 months for 1 year and then annually for 4 years.. In two phase II trials, many subjects who received Lucanix™ at the same dose that will be administered in this trial had long-term disease stability with a good quality of life. ...
Blood samples are collected and analyzed for routine chemistry, cytokines, chemokines, and some instances circulating tumor cells, including response to multiple lung cancer-associated antigens by IFN-γ ELISPOT CD8+ assay; CEA by CD4 class II assay; lung tumor-associated antigens by in vitro proliferation assays; regulatory T-cell (Treg) phenotype by flow cytometry; and Treg function.. Subjects complete the Lung Cancer Symptom Scale quality of life questionnaire at baseline, on the days of treatment, 30 days after completion of study treatment, and then every 3 months for 1 year.. After completion of study treatment, subjects are followed every 3 months for 1 year and then annually for 4 years.. In two phase II trials, many subjects who received Lucanix™ at the same dose that will be administered in this trial had long-term disease stability with a good quality of life. ...
TY - JOUR. T1 - Personalized dendritic cell-based tumor immunotherapy. AU - Janikashvili, Nona. AU - Laemonier, Nicolas. AU - Katsanis, Emmanuel. PY - 2010/1. Y1 - 2010/1. N2 - Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their ...
Looking for Cancer Antigens? Find out information about Cancer Antigens. A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of... Explanation of Cancer Antigens
The tumor marker CA242 is defined by the monoclonal antibody C242. The chemical structure of the antigenic determinant is not exactly known, but the determinant have been shown to be a sialylated carbohydrate structure. In serum, CA242 is found on the same mucin-complex as CA50 and sialylated Lewisa (CA19-9). Thus, CA242 is related, but not identical to the epitope of CA19-9 (1, 2). Serum levels of CA242 are low in healthy subjects and subjects with benign diseases, while elevated levels are commonly found in serum from patients with gastro-intestinal cancer (3). The CA242 marker may be used as an aid in the diagnosis and management of patients with known or suspected gastro-intestinal carcinomas (4-9). The CanAg CA242 EIA should not be used as a substitute for any established clinical examination of malignancy, but may be used as a complement to existing clinical and laboratory methods. ...
Buy anti-TF3C3 antibody, Rabbit anti-Human, Mouse TF3C3 Antibody-NP_001193703.1 (MBS855334) product datasheet at MyBioSource, Primary Antibodies. Application: Western Blot (WB), ELISA (EIA)
ca 15 3 normal range breast cancer - 28 images - ppt tumor markers powerpoint presentation id 6610494, clinical and technical evaluation of acs br serum assay of, introduction of cancer markers laboratory services, human cancer antigen ca15 3 breast cancer calibrator, ppt tumor markers powerpoint presentation id 6610494
Four commercially available Factor Xa (FXa) reagents were evaluated in a fluorogenic anti-FXa assay. The four reagents - of which three were of human origin and the fourth was bovine - were compared in terms of the resulting assay dynamic ranges, lag times, CV and R2 values, sum of squares as well as their sensitivity to unfractionated heparin (UFH) within the therapeutic range of 0-1.2 U mL-1. Based on a balance of performance characteristics, an optimum reagent was selected which had the best combination of all parameters. The best performing serine endopeptidase in the fluorogenic anti-FXa assay was found to be bovine in nature and in liquid form. The resulting assay was very sensitive within the dynamic range of 0-1.2 U mL-1 showing a linear semi-logarithmic dose-response calibration curve with an R2 of 0.99 and CVs%. Of the three human FXa evaluated, the lyophilised human FXa in the absence of stabilizers was demonstrated to be the best performing human FXa reagent. It showed similar behaviour to
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Scientists from Germany today reported a major advance toward opening the doors of a carbohydrate-based medicine chest for the 21st Century. Much more than just potatoes and pasta, these carbohydrates may form the basis ...
Talk About Curing Autism is a nonprofit 501(c)(3) organization. Your donations are fully tax-deductible to the extent allowable by law. If you have any questions or have difficulty completing the form, please contact us.. Your support makes our vital work possible. Wed like to keep in touch with you to tell you more. If you dont want to hear more from TACA just let us know.. Federal Tax ID# 27-0048002. ...
Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor markers play a critical role in the monitoring of patients. The patients clinical status and response to treatment can be evaluated rapidly using the tumor marker half-life (t(1/2)) and the tumor marker doubling time (DT). This report reviews the interest of determining these kinetic parameters for prostate-specific antigen, human chorionic gonadotropin, alpha-fetoprotein, carcinoembryonic antigen, cancer antigen (CA) 125, and CA 15-3. A rise in tumor markers (DT) is a yardstick with which benign diseases can be distinguished from metastatic disease, and the DT can be used to assess the efficacy of treatments. A decline in the tumor marker concentration (t(1/2)) is a predictor of possible residual disease if the timing of blood sampling is soon after therapy. The discrepancies in results obtained by different groups may be attributable to the multiplicity of immunoassays, the intrinsic characteristics of each
iCancer Vaccines and Tumor Immunity/i offers a review of the basic scientific discoveries that have moved forward into clinical trials. Presented in the context of real-world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation, T-regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future.bContributors./bpbForeword./b Cancer Vaccines and Cancer Immunotherapy. A New Paradigm(Jeffrey Schlom).pbPART I. INTRODUCTION./bpChapter 1. Cancer Vaccines. Progress and Promise (Rimas J. Orentas, Bryon Johnson, and James Hodge).pbPART II. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE./bpChapter 2. Fully Synthetic Carbohydrate-Based Anti-Tumor Vaccines (Rebecca M. Wilson and Samuel J. Danishefsky).pChapter 3. Bacillus Calmette-Guerin Immunotherapy of Genitourinary Cancer (Donald ...
A 76-year-old man who suffered from remnant gastric cancer was transferred to our hospital. He previously underwent distal gastrectomy, D1+ lymphadenectomy, and Billroth-I reconstruction for early gastric cancer in another hospital at 63 years of age. The histopathological examination showed pStage IA gastric cancer according to the Japanese Classification of Gastric Carcinoma, 14th edition [7]. A gastrointestinal endoscopic checkup after gastrectomy revealed an ulcerative lesion located on the lesser curvature of the remnant stomach. The histopathological examination of a biopsy specimen revealed well-differentiated tubular adenocarcinoma. After being transferred to our hospital, hematologic examinations including tumor markers, such as carcinoembryonic antigen, α-fetoprotein, carbohydrate antigen 19-9, and carbohydrate antigen 125, were within the normal range, except for the total protein level, which was slightly low (6.5 g/dL). An upper gastrointestinal series showed a 12-mm Type 0-IIc ...
According to an upcoming article in the December 15th issue of Cancer (Cancer 2003;98) a research group from the Harvard Medical School, Boston, under Dr. Brian Liu describes a micro-dissection method where prostatic tissue from 17 suspected cancer patients were examined with a spectroscopic method for a new protein marker, the cellular protein PCa-24). This was found to be positive in 16 of the 17 samples. In contrast, 12 patients with benign prostatic hyperplasia (also known as BPH or "benign prostatic hypertrophy") showed no trace of this prostate cancer specific protein. As this protein is located inside the prostate cancer cell (it is a cellular protein), one has to obtain a tissue sample through a prostate biopsy. The group under Dr. Liu achieved this through laser capture micro-dissection Proteomics, which is the method that was used to characterize the prostate cancer specific protein (PCa-24), is briefly discussed under this link, but it is not necessary to understand all of the ...

KAKEN - Research Projects | Application of novel tumor associated carbohydrate antigen as tumor marker (KAKENHI-PROJECT...KAKEN - Research Projects | Application of novel tumor associated carbohydrate antigen as tumor marker (KAKENHI-PROJECT...

Application of novel tumor associated carbohydrate antigen as tumor marker. Research Project ... We aimed to generate monoclonal antibodies specifically recognize tumor associated carbohydrate antigen, Sialyl Type 1H (ST1H ...
more infohttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23501303/

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation - American College...Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation - American College...

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation. May 20, 2013 ... YOU ARE HERE: Home , Latest in Cardiology , Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter ... What is the predictive value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve ...
more infohttp://www.acc.org/latest-in-cardiology/journal-scans/2013/05/20/16/03/tumor-marker-carbohydrate-antigen-125-predicts-adverse-outcome

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation | JACC:...Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation | JACC:...

Tumor marker carbohydrate antigen 125 (CA125) is an emerging cardiac biomarker. In heart failure (HF), CA125 has shown to be ... Objectives This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after ... Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation ... Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation ...
more infohttp://interventions.onlinejacc.org/content/6/5/487

KAKEN - Research Projects | Development of immunotherapy for brain tumors targeting carbohydrate antigens of glycolipids ...KAKEN - Research Projects | Development of immunotherapy for brain tumors targeting carbohydrate antigens of glycolipids ...

Development of immunotherapy for brain tumors targeting carbohydrate antigens of glycolipids. Research Project ... Publications] T.Yamaki: The requirement of host immune response to tumor cells to achieve tumor eradication by intratumoral ... Publications] Yamaki T.: The requirement of host immune response to tumor cells to achieve tumor eradication by intratumoral ... Publications] T.Yamaki: The requirement of host immune response to tumor cells to achieve tumor eradication by intratumoral ...
more infohttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-05807129/

reagents-immunoassay-tumor-marker-carbohydrate-antigen-mcareagents-immunoassay-tumor-marker-carbohydrate-antigen-mca

"Carbohydrate Antigen MCA Determination Reagents" , "Reagents, Immunoassay, Tumor Marker, Carbohydrate Antigen MCA" ... mucinlike carcinoma-associated antigen), a carbohydrate-related tumor marker. The detection of the tumor marker MCA is mostly ... IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen MCA. Definition : Immunoassay reagents intended to ... Home > Specialties > IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen MCA ...
more infohttp://www.medicalproductguide.com/term/5565/reagents-immunoassay-tumor-marker-carbohydrate-antigen-mca

reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-549reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-549

Carbohydrate Antigen 549) Determination Reagents" , "Reagents, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 549" ... IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 549. Definition : Immunoassay reagents intended to ... Home > Specialties > IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 549 ... a carbohydrate-related tumor marker. The detection of the tumor marker CA 549 is mostly used in monitoring therapy, disease ...
more infohttp://www.medicalproductguide.com/term/5564/reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-549

reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-15-3reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-15-3

Carbohydrate Antigen 15-3) Determination Reagents" , "Reagents, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 15-3" ... a carbohydrate-related antigen tumor marker. The detection of the tumor marker CA 15 is mostly used in monitoring therapy and ... Home > Specialties > IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 15-3 ... IVD Test Reagent/Kits, Immunoassay, Tumor Marker, Carbohydrate Antigen CA 15-3. ...
more infohttp://productguide.optometricmanagement.com/term/4899/reagents-immunoassay-tumor-marker-carbohydrate-antigen-ca-15-3

Synthesis And Vaccine Evaluation Of The Tumor Associated Carbohydrate Antigen Rm2 From Prostate CancerSynthesis And Vaccine Evaluation Of The Tumor Associated Carbohydrate Antigen Rm2 From Prostate Cancer

... by Guy 3 ... Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 come to share garlands like a WARFARE would. ... The critical Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen nostro is non Fresh Air from the ... How several receive the horizons in your Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 from ...
more infohttp://miggsb.com/FS/js/lib.php?q=Synthesis-and-Vaccine-Evaluation-of-the-Tumor-Associated-Carbohydrate-Antigen-RM2-from-Prostate-Cancer/

Oncotarget | Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in...Oncotarget | Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in...

... a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects ... a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects ... Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast ... Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. ...
more infohttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=21959&path%5B%5D=69621

Carbohydrates in Drug Design and Discovery (RSC Publishing)Carbohydrates in Drug Design and Discovery (RSC Publishing)

... this book comprehensively covers the new and recent discoveries in the area of carbohydrate drug discovery.Carbohydrates in ... and the use of synthetic ligands based on carbohydrates as drugs has received much attention. Focussing on drug discovery from ... In recent years there has been increasing evidence of the importance of carbohydrates and glycoconjugates in biomedical ... Boosting Humoral Immune Responses to Tumor-associated Carbohydrate Antigens with Virus-like Particles. Zhaojun Yin and Xuefei ...
more infohttp://pubs.rsc.org/en/content/ebook/978-1-84973-939-9

Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and...Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and...

S. Zhang, C. Cordon Cardo, H. S. Zhang et al., "Selection of carbohydrate tumour antigens as targets for immune attack using ... Kawachi and Saida suggested that HD antigen is expressed on the carbohydrate chains of glycoproteins but not on those of ... These changes allow considering some gangliosides as tumor-associated antigens and they have been selected as possible target ... "Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human ...
more infohttps://www.hindawi.com/journals/isrn/2011/848909/

Rueda Lab:  Bo Rueda, PhD - Massachusetts General Hospital, Boston, MARueda Lab: Bo Rueda, PhD - Massachusetts General Hospital, Boston, MA

Tumor-associated carbohydrate antigens (TACAs) are promising therapeutic targets. Increased presence of Sialyl-Thomsen-nouveau ... Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. ... These explanted tumors and the primary tumors are genotyped and undergo cryopreservation using state of the art techniques. ... Molecular interrogation of gynecologic tumors.. My group molecularly interrogates gynecologic tumors to identify genes or ...
more infohttps://www.massgeneral.org/vcrb/research/researchlab.aspx?id=1754

Frontiers | Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses | ImmunologyFrontiers | Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses | Immunology

... consequences of mimicking tumor associated carbohydrate antigens and the notion of reverse engineering to develop carbohydrate ... consequences of mimicking tumor associated carbohydrate antigens and the notion of reverse engineering to develop carbohydrate ... Here, we discuss our experience in bringing a tumor-associated carbohydrate mimetic peptide to the clinic. Emphasis is placed ... Here, we discuss our experience in bringing a tumor-associated carbohydrate mimetic peptide to the clinic. Emphasis is placed ...
more infohttps://www.frontiersin.org/articles/10.3389/fimmu.2014.00308/full

What Makes a Cancer Cell a Cancer Cell? - Holland-Frei Cancer Medicine - NCBI BookshelfWhat Makes a Cancer Cell a Cancer Cell? - Holland-Frei Cancer Medicine - NCBI Bookshelf

Tumor-associated carbohydrate antigens can also be classified by the cell types expressing them as those (1) expressed on only ... Tumor-associated carbohydrate antigens can be classified into three groups38: (1) epitopes expressed on both glycolipids and ... Clinical trials of mucin-derived vaccines are underway.58 Some mucin antigens are shed from tumor cells and can be detected in ... by the fact that many of the monoclonal antibodies developed to tumor-cell-associated antigens recognize these carbohydrate ...
more infohttps://www.ncbi.nlm.nih.gov/books/NBK12516/

Faculty for Chemistry and Pharmacy LMU Munich - Prof. Dr. Anja Hoffmann-RöderFaculty for Chemistry and Pharmacy LMU Munich - Prof. Dr. Anja Hoffmann-Röder

Synthesis of carbohydrates, peptides and glycokonjugates. *Tumor-associated carbohydrate antigens and cancer vaccines ... A. Hoffmann-Röder, J. Schoenhentz, S. Wagner, E. Schmitt, "Perfluoroalkylated amphiphilic MUC1 glycopeptide antigens as tools ... "Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a ...
more infohttp://www.cup.uni-muenchen.de/de/departments/chemie/personen/prof-dr-anja-hoffmann-roeder/

Multicystic dysplastic kidney: absence of complications in patients treated conservatively. - Semantic ScholarMulticystic dysplastic kidney: absence of complications in patients treated conservatively. - Semantic Scholar

Persistent High Level of Urinary Tumor Marker Carbohydrate Antigen 19-9 in Prenatally Diagnosed Dysplastic Kidney. Reza ... Risk of Wilms tumour with multicystic kidney disease: a systematic review.. Hassib Narchi ...
more infohttps://www.semanticscholar.org/paper/Multicystic-dysplastic-kidney%3A-absence-of-in-Orejas-M%C3%A1laga/fdaecbcd3bbe9bf634f5a4ab5f021937109d0a1e

Plus itPlus it

Hakomori S. Possible functions of tumour-associated carbohydrate antigens. Curr. Opin. Immunol., 3: 646-653, 1991. ... Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother., 43: 152-157, 1996 ... Selection of tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int. J. Cancer, ... We also examined antigen-binding specificity by ganglioside-binding ELISA (12) . The humanized KM8969 reacted strongly with N- ...
more infohttp://cancerres.aacrjournals.org/content/59/20/5323

Applications filed at Feb 01 2018 | METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR | Patents.comApplications filed at Feb 01 2018 | METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR | Patents.com

METHOD FOR TREATING A TUMOR WITH BIFUNCTIONAL AGENTS THAT BIND TO TUMOR CARBOHYDRATE ANTIGENS. A method for treating a tumor ... NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF. Novel minor histocompatibility antigens (MiHAs) are described. These ... COMPOSITION AND METHOD FOR AFFECTING THE BINDING OF ANTIGEN-BINDING POLYPEPTIDES TO ANTIGENS. The present invention provides a ... The antibody or antigen-binding portion thereof may... 2018/0030117. Synthetic Single Domain Antibody. The invention relates to ...
more infohttp://patents.com/ap-20180201-p109.html

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis | SpringerLinkJoint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis | SpringerLink

Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc ... Joint modeling tumor burden and time to event data in oncology trials. Pharm Stat. 2014;13(5):286-93.PubMedCrossRefGoogle ... Joint longitudinal and survival-cure models in tumour xenograft experiments. Stat Med. 2014;33(18):3229-40.PubMedCrossRefGoogle ... Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of ...
more infohttps://link.springer.com/article/10.1186/s12874-016-0272-6

A comparison of multiple urine markers for interstitial cystitis<...A comparison of multiple urine markers for interstitial cystitis<...

Tumor-Associated Carbohydrate Antigens Methylhistamines Nocturia Control Groups Hyaluronic Acid Nitrites Glycosaminoglycans ...
more infohttps://pennstate.pure.elsevier.com/en/publications/a-comparison-of-multiple-urine-markers-for-interstitial-cystitis

Cathy S Carlson - Research Output
     - Experts@MinnesotaCathy S Carlson - Research Output - [email protected]

The novel carbohydrate tumor antigen C2-O-sLex is upregulated in canine gastric carcinomas. Janke, L., Carlson, C. S. & St. ... Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and ... The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance. Kumari, R., Li ...
more infohttps://experts.umn.edu/en/persons/cathy-s-carlson/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle

Plus itPlus it

Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52: 257-331, 1989. ... Among the 10 tumors with low GnT-V expression, 6 tumors had low L-PHA staining, and 2 tumors had moderate L-PHA staining. ... Among the 10 tumors with high GnT-V expression, 6 tumors had high L-PHA staining, and 2 tumors had moderate L-PHA staining. ... The staining pattern of a tumor with high GnT-V expression and high L-PHA staining is shown in A and B. Staining for a tumor ...
more infohttp://clincancerres.aacrjournals.org/content/10/5/1773

Dr. Salvatore Patanè, MD - Cardiologia Ospedale San Vincenzo Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada...Dr. Salvatore Patanè, MD - Cardiologia Ospedale San Vincenzo Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada...

Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass.. Authors:. Salvatore Patanè ... Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going?. Authors:. Salvatore ... Prostate-specific antigen kallikrein complexes and acute myocardial infarction.. Authors:. Salvatore Patanè Filippo Marte Mauro ... Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system.. Authors:. Salvatore Patanè Filippo Marte ...
more infohttps://www.pubfacts.com/author/Salvatore+Patane
  • Purpose: N -Acetylglucosaminyltransferase V (GnT-V), a key enzyme in the formation of branching of asparagine-linked oligosaccharides, is strongly linked to tumor invasion and metastasis of colon and breast cancers. (aacrjournals.org)
  • Biancone L, Araki M, Araki K et al (1996) Redirection of tumor metastasis by expression of E-selectin in vivo. (springer.com)
  • To investigate the mechanisms underlying cell surface carbohydrate-dependent cancer metastasis, we developed a 7-mer peptide, designated as I-peptide, which is capable of inhibiting FUT3-transfected B16 cell colonization of lung in the mouse. (springer.com)
  • Borsig L, Wong R, Hynes RO, Varki NM, Varki A (2002) Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. (springer.com)
  • To induce sustained immunity against both LeY and GD2, we developed a carbohydrate mimicking peptide (CMP) as a surrogate pan-immunogen that mimics both. (oncotarget.com)
  • Recently, however, Hahn and colleagues 28 showed that ectopic expression of the human telomerase catalytic subunit (human telomerase reverse transcriptase [hTERT]) in combination with the oncogenes h- ras and SV40 virus large-T antigen can induce tumorigenic conversion in normal human epithelial and fibroblast cells, suggesting that disruption of the intracellular pathways regulated by these gene products is sufficient to produce a malignant cell. (nih.gov)
  • Such strategies could produce organisms that perform multistep immune functions such as presenting antigen to and co-stimulating helper T cells in a specific manner, or providing integrated signals to B cells to induce affinity maturation and isotype switching during antibody production. (wikipedia.org)
  • Publications] Y.Ibayashi: 'Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients' Neurologia medico-chirurgica. (nii.ac.jp)
  • More recently, the study was extended to cutaneous melanomas and their metastases [ 12 ] and to epithelial tumors of the digestive system [ 13 ]. (hindawi.com)
  • Several types of cancer, especially epithelial carcinomas such as pancreatic cancer, commonly display particular carbohydrate alterations that have potential functional roles in cancer progression. (springer.com)
  • To characterize the safety and immunogenicity of a heptavalent antigen-keyhole limpet hemocyanin (KLH) plus QS21 vaccine construct in patients with epithelial ovarian, fallopian tube, or peritoneal cancer in second or greater complete clinical remission. (aacrjournals.org)
  • For the production of antibodies against defined cell surface antigens such as these, the best approach has been described to include chemical conjugation of the antigen to a highly immunogenic carrier protein plus the use of a potent immunologic adjuvant. (aacrjournals.org)
  • To this end we utilize a well-established in vivo experimental system in which primary tumors collected from ovarian and endometrial cancer patients at the time of initial surgery are grown in NOD/SCID mice. (massgeneral.org)
  • Increased presence of Sialyl-Thomsen-nouveau antigen (STn), a TACA, correlates with worsened outcome and chemoresistance in ovarian cancer (OvCa). (massgeneral.org)
  • The reactivity of monoclonal antibodies against those gangliosides was examined next either as chemically isolated antigens or cell surface ones. (nii.ac.jp)
  • Serologic responses by ELISA were largely IgM against each antigen with the exception of Tn-MUC1 where both IgM and IgG responses were induced. (aacrjournals.org)
  • However, many of the biochemical characteristics initially thought to be closely associated with the malignant phenotype of cells in culture were subsequently found to be dissociable from the ability of those cells to produce tumors in animals. (nih.gov)
  • Furthermore, individual cells of malignant tumors growing in animals or in humans exhibit marked biochemical heterogeneity, as reflected in their cell surface composition, enzyme levels, immunogenicity, response to anticancer drugs, and so on. (nih.gov)
  • There should be a variety of factors that influence the antibody reactions against glycolipid antigens. (nii.ac.jp)
  • We are now focusing on the glycolipid analysis of surgical specimens of glioma tissue as well as on the factors participating in the antibody reactivity against those antigens. (nii.ac.jp)
  • A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent. (patents.com)
  • Some of these characteristics may be seen both in transformed cells in culture and in tumors growing in vivo in experimental animals or patients. (nih.gov)
  • Campbell BJ, Finnie IA, Hounsell EF et al (1995) Direct demonstration of increased expression of Thomsen−Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. (springer.com)
  • Our work to date provides evidence to suggest the clinical course of the primary tumor mimics the behavior and responses we have seen in our explants further supporting the potential clinical utility of our xenograft model. (massgeneral.org)
  • Eight of nine patients developed responses against at least three antigens. (aacrjournals.org)
  • Antibodies are well suited for eradicating tumor cells from the bloodstream and eliminating early tissue invasion ( 4 ). (aacrjournals.org)
  • This allows for the generation of large cohorts of matched xenograft tumors ready for use in multi-armed therapeutic experiments. (massgeneral.org)
  • I-peptide inhibited lung colonization of FUT3-B16 cells in E-/P-selectin doubly deficient mutant mice, suggesting the existence of an as yet unidentified carbohydrate-binding endothelial receptor distinct from E-/P-selectins. (springer.com)
  • Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M (2000) A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. (springer.com)
  • One to two percent of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. (wikipedia.org)
  • Among biological characteristics of tumors, Ki-67 labeling index was higher in tumors with low GnT-V expression than in those with high GnT-V expression, although this difference was not statistically significant ( P = 0.09). (aacrjournals.org)
  • Focussing on drug discovery from key targets and placing an emphasis on the multi-disciplinary approaches necessary to challenge these issues, this book comprehensively covers the new and recent discoveries in the area of carbohydrate drug discovery. (rsc.org)
  • Assess postimmunization changes in prostate specific antigen levels and other objective parameters of disease in these patients. (bioportfolio.com)
  • Provenge is an adoptive cell-transfer therapy in which a patient's antigen-presenting target autologous prostate cancer tissue. (wikipedia.org)
  • Consequently, certain carbohydrate forms profoundly affect both the pathophysiology of infection and neoplasia (Table 1 ). (frontiersin.org)
  • Publications] B.O.Choi: 'Biochemical analysis of cytokine effect on the glycosphingolipid expression of human glioma cell lines' Tumor Res.28. (nii.ac.jp)
  • These explanted tumors and the primary tumors are genotyped and undergo cryopreservation using state of the art techniques. (massgeneral.org)
  • Furthermore, β1-6 branching of asparagine-linked oligosaccharides, which are products of GnT-V, were increased highly or moderately in 8 of 10 tumors with high GnT-V expression, as judged by leukoagglutinating phytohemagglutinin staining. (aacrjournals.org)